Latest stories on VCYT
Phase III Trial Shows Veracyte’s Decipher Prostate Test Can Predict Benefit from Adding Abiraterone to Treatment in Very High-Risk Prostate Cancer
Business Insider74 · bullishproduct/pr
Veracyte: Strong Diagnostic Growth And Improving Margins
Seeking Alpha64 · neutralanalyst
Veracyte Spotlights “First Evidence” Decipher Prostate Signal for Abiraterone Benefit Ahead of ESMO 2026
October 19, 2026
MarketChameleon64 · neutralproduct/pr
Six Studies to Highlight Veracyte’s Genomic Tests Across Breast, Prostate and Bladder Cancer at ESMO 2026
GlobeNewswire58 · neutralproduct/pr
Six Studies to Highlight Veracyte’s Genomic Tests Across Breast, Prostate and Bladder Cancer at ESMO 2026
Business Insider58 · neutralproduct/pr
Veracyte to Release Third Quarter 2026 Financial Results on November 4, 2026
Business Insider50 · neutralgeneral
Veracyte to Release Third Quarter 2026 Financial Results on November 4, 2026
GlobeNewswire50 · neutralgeneral
Cathie Wood’s Ark weekly recap: cuts SpaceX exposure alongside HOOD, TER, boosts CRWV, VCYT
Seeking Alpha54 · neutralgeneral
Cathie Wood Loads Up On These Biotech Stocks After Strong Rallies – Unloads $18M Worth Of TWST Shares
Stocktwits News63 · neutralgeneral
Cathie Wood’s ARK Investment buys 115.5K shares of Veracyte today
The Fly63 · neutralgeneral
Cathie Wood’s ARK Investment buys 159K shares of Veracyte today
The Fly63 · neutralgeneral
Veracyte announces new findings from Phase III NRG/RTOG 0815 trial
The Fly59 · neutralproduct/pr
Phase III Trial Demonstrates Veracyte’s Decipher Prostate Test Predicts Benefit from Adding Hormone Therapy to Radiation
GlobeNewswire73 · bullishproduct/pr
Veracyte Announces Eight Decipher-Focused Studies to Be Presented at ASTRO 2026
GlobeNewswire63 · neutralproduct/pr
Veracyte Announces Eight Decipher-Focused Studies to Be Presented at ASTRO 2026
StockTitan63 · neutralproduct/pr
Veracyte, Inc. (VCYT) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Seeking Alpha55 · neutralgeneral
Needham reiterates Veracyte stock rating at Buy on genomics deal
Investing.com Analyst Ratings61 · neutralanalyst
Veracyte acquiring Convergent Genomics in up to $180M deal
Seeking Alpha63 · neutralm&a
Veracyte acquires Convergent Genomics for $150M in cash upfront
The Fly63 · neutralm&a
VERACYTE, INC. (VCYT) files 8-K
SEC 8-K50 · neutralgeneral
Veracyte assumed with a Buy at UBS
The Fly61 · neutralanalyst
VCYT Drops 25.3% in the Past Month. Is the Sell-Off an Opportunity?
Quartz48 · neutralgeneral
Veracyte to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference
StockTitan55 · neutralgeneral